5. Jubiläum: Die ICPO Foundation gestaltet eine neue Ära der Krebsbehandlung mit Radiotheranostik für Patienten weltweit
5. Jubiläum: Die ICPO Foundation gestaltet eine neue Ära der Krebsbehandlung mit Radiotheranostik für Patienten weltweit
12. Dezember 2024 04:00 ET | ICPO Foundation
Mit der Einführung der "ICPO Academy for Theranostics" und dem Aufbau eines globalen Netzwerks von ICPO-Centern hat sich die Foundation als international führend in der Wissensvermittlung und der...
5th Anniversary: ICPO Foundation is empowering a new era of cancer treatment with Radiotheranostics for patients world
5th Anniversary: ICPO Foundation is empowering a new era of cancer treatment with Radiotheranostics for patients worldwide
12. Dezember 2024 04:00 ET | ICPO Foundation
Launching the "ICPO Academy for Theranostics" and creating its global network of ICPO Centers, the foundation has become an international leader in sharing knowledge and shaping standards in its...
Balanced Green Primary Logo Medium 1000px.png
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
05. Dezember 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
22157.jpg
Comprehensive Epidemiology Forecast Reveals Significant Insights into Prader-Willi Syndrome Through 2034
02. Dezember 2024 04:42 ET | Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...
Revolution Medicines.jpg
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
27. November 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
22157.jpg
10 year 8 Major Market Bladder Cancer Epidemiology Forecasts 2023-2033
18. November 2024 10:20 ET | Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Revolution Medicines.jpg
Revolution Medicines to Participate in Upcoming Investor Conferences
05. November 2024 09:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Synox Logo.jpg
SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial
30. Oktober 2024 07:00 ET | SynOx Therapeutics Limited
Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
23. Oktober 2024 07:00 ET | EvolveImmune
Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...